KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2016 - 2025)

Rigel Pharmaceuticals has reported Total Current Liabilities over the past 16 years, most recently at $99.2 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $99.2 million for Q4 2025, up 56.77% from a year ago — trailing twelve months through Dec 2025 was $99.2 million (up 56.77% YoY), and the annual figure for FY2025 was $99.2 million, up 56.77%.
  • Total Current Liabilities for Q4 2025 was $99.2 million at Rigel Pharmaceuticals, up from $94.4 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for RIGL hit a ceiling of $99.2 million in Q4 2025 and a floor of $44.0 million in Q2 2023.
  • Median Total Current Liabilities over the past 5 years was $59.3 million (2021), compared with a mean of $62.4 million.
  • Biggest five-year swings in Total Current Liabilities: dropped 23.14% in 2023 and later soared 73.81% in 2025.
  • Rigel Pharmaceuticals' Total Current Liabilities stood at $63.6 million in 2021, then increased by 2.61% to $65.2 million in 2022, then fell by 18.32% to $53.3 million in 2023, then increased by 18.83% to $63.3 million in 2024, then surged by 56.77% to $99.2 million in 2025.
  • The last three reported values for Total Current Liabilities were $99.2 million (Q4 2025), $94.4 million (Q3 2025), and $86.6 million (Q2 2025) per Business Quant data.